Stellaromics, a Boston, MA-based 3D spatial biology company, raised $80M in Series B funding.
The round was led by Catalyst4 with participation from Stanford University Ventures.
The company intends to use the funds to support the development and commercialization of Pyxa, its 3D spatial biology platform.
Led by CEO Todd Dickinson, Stellaromics specializes in 3D spatial multi-omics. Its Pyxa platform enables researchers to visualize and analyze the spatial organization of cells and molecules within thick tissue samples based on its STARmap and RIBOmap technologies.
Key features of Pyxa include:
- Thick tissue analysis
- Sub-cellular resolution, multi-omic spatial profiling.
- Simplified workflow.
- Advanced visualization software.
The system is available for order now, with an early access program already fully subscribed and set to launch in the second half of 2025. Initial commercial shipments are estimated to begin at the end of 2025. To support researchers interested in generating pilot data for a Pyxa system, Stellaromics offers a dedicated services program.
FinSMEs
11/02/2025